Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing LUCENTIS®ii (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEA®iii (aflibercept), is in pre-clinical development.
In addition, the agreement provides Biogen an option to extend the commercialization term for Samsung Bioepis’ three anti-TNF biosimilars – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) – in Europe for additional five years, extending the original ten-year agreement.1 BENEPALI™ is the most prescribed etanercept in France, Germany, Italy, Spain, and the United Kingdom (UK).iv IMRALDI™ is the leading adalimumab biosimilar in Europe.iv
The agreement also provides Biogen an option to receive commercialization rights to BENEPALI™, FLIXABI™ and IMRALDI™ in China in exchange for royalties on sales in the market.
The agreement is a testament to Samsung Bioepis’ strong track record in the field of biosimilars and the potential value that Samsung Bioepis’ ophthalmology biosimilars could deliver to patients and healthcare systems across the world. Under the agreement, Samsung Bioepis will receive upfront payments of USD 100 million, up to USD 270 million in milestone/option payments, as well as sharing of sales revenue. Samsung Bioepis will be responsible for development, regulatory registration, and manufacture of the products, while Biogen will be responsible for commercialization.
“In Europe, we have been very pleased with Biogen’s commercialization efforts with our anti-TNF medicines, fulfilling the mission of expanding access to high-quality medicines to patients across Europe. By building on this collaboration, we are excited to potentially expand the opportunity for patients living with ophthalmological conditions, who don’t have access to life-changing medicines,” said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”
Samsung Bioepis’ products are now available across Europe, North America, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.
1 The effective dates of commercialization differ for each anti-TNF product based on the launch dates. BENEPALI ™ and FLIXABI ™ were launched in Europe in January and May 2016, respectively, while IMRALDI ™ was launched in October 2018 in Europe.
About BENEPALI™ (etanercept)
BENEPALI™ (etanercept), a biosimilar referencing ENBREL®v, was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis, pediatric plaque psoriasis. BENEPALI™ is currently available in 25 countries in Europe and is the most prescribed etanercept in France, Germany, Italy, Spain and the United Kingdom.iv
About FLIXABI™ (infliximab)
FLIXABI™ (infliximab), a biosimilar referencing REMICADE®vi, was approved by the European Commission (EC) in May 2016 for the treatment of adults with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis. FLIXABI™ can also be used in patients 6-17 years old with severe, active Crohn’s disease or severely active ulcerative colitis when they have not responded to or cannot take other medicines or treatments. FLIXABI™ is currently available in 17 countries in Europe.iv
About IMRALDI™ (adalimumab)
IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®vii, was approved by the European Commission (EC) in August 2017 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, uveitis, and pediatric uveitis. IMRALDI™ is currently available in 19 countries in Europe and is the leading adalimumab biosimilar in Germany and in Europe year to date 2019. iv, viii
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.
i Data on file: Biogen, Inc. Third Quarter 2019 Financial Results and Business Update, Oct 22, 2019
ii LUCENTIS® is a registered trademark of Genentech
iii EYLEA® is a registered trademark of Regeneron Pharmaceuticals
iv Data on File: IQVIA, GERS, Insight Health ODV
v ENBREL® is a registered trademark of Pfizer/Amgen
vi REMICADE® is a registered trademark of Janssen
vii HUMIRA® is a registered trademark of AbbVie
viii Data on File: Biogen data on file
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005515/en/
Contact information
MEDIA CONTACT:
Na Yun KIM
+82-31-8061-1604
nayun86.kim@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe Conference Focusing on Applied AI Is Sold Out3.11.2025 15:30:00 EET | Press release
Phenom, the leader in applied AI that helps organisations hire faster, develop better and retain longer, announced its first IAMPHENOM Europe conference — the only applied AI event for human resources in the region — is sold out. A waitlist is available on a first-come, first-serve basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103977081/en/ Phenom announced its first IAMPHENOM Europe conference — the only applied AI event for human resources in the region — is sold out. A waitlist is available on a first-come, first-serve basis. The in-person event taking place in Munich on 6 November will feature visionary keynotes, customer-led breakout sessions, live demonstrations of use-case specific AI agents, and networking opportunities across HR and IT. With 25+ speakers across 15+ sessions and breakouts, session topics will include how to: Assess AI and automation maturity levels Deploy 25+ AI agents Uphold compliance wh
World No.1 Achievement: AGENCIA’s “360°Car®” Certified by GUINNESS WORLD RECORDS™3.11.2025 15:30:00 EET | Press release
AGENCIA Inc. (Headquarters: Nagoya, Japan; CEO: Jean Pierre), a leading innovator in automotive digital transformation through artificial intelligence (AI) and 360° imaging, today announced that its proprietary SaaS platform “360°Car®” has been officially certified by GUINNESS WORLD RECORDS™ as the “Largest online album of 360° car views,” achieving an unprecedented 7,096,049 vehicle images. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251031167896/en/ [GUINNESS WORLD RECORDS™ Title] AGENCIA “360°Car®” Achieves World No. 1 with 7,096,049 360° Vehicle Images This world record establishes AGENCIA as a global pioneer in automotive visualization and AI-driven digital infrastructure, redefining how vehicles are inspected, presented, and traded worldwide. Transforming Automotive Transparency through AI × 360° Imaging Over the past decades, the automotive industry—particularly the used-car segment—has continually sought to enhanc
Blackstone Credit & Insurance Appoints Laura Coady as Global Head of CLOs and European Head of Liquid Credit Strategies3.11.2025 14:10:00 EET | Press release
Blackstone (NYSE: BX) announced today that Laura Coady, formerly Head of International Securitised Markets and Global Head of CLOs at Jefferies, has joined Blackstone Credit & Insurance (“BXCI”) as Global Head of CLOs and European Head of Liquid Credit Strategies (LCS). Based in London, Coady will oversee BXCI’s CLO activity globally, including CLO formation and investing, and lead the liquid credit business in Europe. BXCI’s LCS business manages $120 billion across corporate bonds, leveraged loans, CLOs and Multi-Asset Credit. Blackstone is the largest global manager of CLOs and loans, and the most active loan trader. The firm set a record for global annual CLO issuance in 2024, beating the previous record set by Blackstone in 2021. Dan Leiter, Head of International and Global Head of Liquid Credit Strategies for BXCI, said: “We’re thrilled to welcome Laura to further strengthen our global CLO franchise and expand our liquids business across Europe. We believe our momentum in these ar
AMINA Becomes the First Crypto Banking Group to Receive a MiCA License Through Its Austrian Subsidiary3.11.2025 14:04:00 EET | Press release
AMINA Bank AG (“AMINA Bank”) today announced that its newly established subsidiary, AMINA (Austria) AG (“AMINA EU”), has received a Crypto-Asset Service Provider (CASP) license from Austria’s Financial Market Authority (FMA) under the Markets in Crypto-Assets (MiCAR) framework. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103510417/en/ AMINA Expands into the EU The FMA’s approval paves the way for AMINA EU’s launch, with regulated crypto trading, custody, and portfolio management services, as well as crypto staking, to be introduced at launch. These offerings will be available to professional investors, including family offices, corporates, financial institutions, and more. AMINA EU, an FMA-licensed crypto-asset service provider, will offer a purpose-built platform giving clients secure, institutional-grade access to the crypto ecosystem. As a wholly owned subsidiary of AMINA Bank and a member of the global AMINA Group,
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation3.11.2025 14:02:00 EET | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience, making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103162356/en/ TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom